Credit Suisse raised the firm’s price target on Natera to $65 from $55 and keeps an Outperform rating on the shares following quarterly results. The firm has a positive view of the company’s growth opportunities in minimal residual disease testing across multiple indications, as well as its continued leading position in reproductive health testing.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NTRA:
- Natera sees FY23 revenue $980M-$1.0B, consensus $988.88M
- Natera reports Q4 EPS ($1.37), consensus ($1.42)
- Personalis price target lowered to $5 from $11 at Morgan Stanley
- Natera price target raised to $80 from $70 at Piper Sandler
- New paper highlights clinical utility of Natera’s Renasight in kidney disease